Cantor Fitzgerald lowered the firm’s price target on Capricor Therapeutics (CAPR) to $22 from $30 and keeps an Overweight rating on the shares. The firm views the complete response letter for deramiocel as a “disappointing setback.” However, the “binary nature” of the upcoming HOPE-3 data makes Capricor’s risk/reward “quite interesting,” the analyst tells investors in a research note. Cantor believes that if the HOPE-3 study is successful, the “argument for approval can grow substantially.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor data in Q3 should support resubmission, says JonesResearch
- Capricor Therapeutics price target lowered to $24 from $77 at H.C. Wainwright
- Capricor Therapeutics’ Deramiocel: Overcoming Setbacks with Promising Phase 3 Trial and Long-term Efficacy Data
- Capricor Therapeutics Stock (CAPR) Plummets 40% on FDA Rejection
- Morning Movers: Capricor Therapeutics plunges following CRL from FDA